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Abstract
Objectives To present and discuss the epidemiolog-
ical and clinical aspects, as well as therapeutic
options and outcome of de novo renal cell carcinoma
(RCC) of the native kidneys in a series of Chinese
renal transplant recipients.
Patients and Methods A retrospective, cohort study
examining all renal transplant recipients with the
diagnosis of RCC of native kidney followed up in
two major regional hospitals in Hong Kong between
January 2000 and December 2009. Clinical data included
age, gender, cause of renal failure, symptoms at pre-
sentation, duration of transplantation, immunosup-
pressive therapy, and history of acquired cystic
kidney disease (ACKD). Laboratory, radiographic,
operative, and pathology reports were used to assess
the tumor extent.
Results Among the 1,003 renal transplant recipients
recruited, 12 transplant recipients had a nephrectomy
for a total of 13 RCC. The prevalence of de novo
RCC was 1.3%. The mean age at diagnosis of RCC
was 48.4 years, and the median time from transplan-
tation to diagnosis was 6.1 years. ACKD was found
in 6 (50%) of the patients. All patients except one
were asymptomatic. pT1 disease was found in ten
patients with a mean tumor size of 3.2 cm. All
patients were treated successfully with radical
nephrectomy. After a median follow-up of 38 months,
two patients (16.7%) died. One died of sepsis, and the
other died of metastatic carcinoma.
Conclusions With increasing data showing a better
prognosis if RCC is detected early by screening, it is
time to consider screening all kidney transplant
recipients for ACKD and RCC.
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Introduction
Renal transplantation remains the best treatment
option for patients with end stage renal disease
(ESRD) for their survival and quality of life. There is
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a significant increased risk of malignancy, most
common skin malignancies and non-Hodgkin lym-
phomas, in renal transplant recipients as a result of
the use of immunosuppressive medication [1]. On
the other hand, carcinoma of the native kidney
accounts for less than 5% of all malignancies found
in transplant recipients [2]. After successful renal
transplantation, the risk of developing renal cell
carcinoma (RCC) in native kidneys is about 15 times
higher than in the normal population [1].
There has been only a few reported series compris-
ing few renal transplant patients with RCC of native
kidneys due to the relative rarity of the condition.
Furthermore, there is scarcity of such data in the Asian
population. In this study, we present and discuss the
epidemiological and clinical aspects, as well as ther-
apeutic options and outcome of de novo RCC of the
native kidneys in our renal transplant recipients.
Patients and methods
This is a retrospective, cohort study examining all renal
transplant recipients with the diagnosis of RCC of native
kidney followed up in two major regional hospitals in
Hong Kong, Queen Mary Hospital and Queen Elizabeth
Hospital, between January 2000 and December 2009.
During the time period examined, there was no protocol
of including routine ultrasound monitoring of native
kidney in all patients as a part of follow-up. Clinical,
pathological, and follow-up data were retrieved from
each patient’s medical record. Clinical data included
age, gender, cause of renal failure, symptoms at
presentation, duration of dialysis, duration of transplan-
tation, immunosuppressive therapy, and history of
acquired cystic kidney disease (ACKD). ACKD was
defined as three or more cysts per kidney on ultrasound
scan [3]. Laboratory, radiographic, operative, and
pathology reports were used to assess the tumor extent.
Tumor stage was determined according to the 2002
TNM classification [4]. The subtype of the tumor was
classified according to the Heidelberg classification of
the kidney tumors [5]. Tumors were graded according to
the Fuhrman scheme [6]. Continuous data are expressed as
means ± standard deviation (SD) while categorical
data are expressed as percentages.
Results
Among the 1,003 renal transplant recipients recruited,
12 transplant recipients had a nephrectomy for a total of
13 RCC. The prevalence of de novo RCC in our present
series was 1.3%. The demographic and clinicopatho-
logic characteristics of our patients were shown in
Table 1 and 2. There were 10 men and two women
with mean age of 40 years (SD 10.6 years; range
27.5–68.3 years) at the time of transplant. Nine patients
Table 1 Demographic data of renal transplant recipients with RCC
Patient
number
Gender ESRD Age at diagnosis
of RCC (years)
Interval between
transplant and RCC
diagnosis (months)
ACKD Immunosuppressive regimen
1 M Chronic GN 46 66 - Pred ? Tac ? MMF
2 F Unknown 70 15 ? Pred ? Tac ? Aza
3 M Chronic GN 47 46 - Pred ? CsA
4 M Unknown 48 147 - Pred ? CsA
5 M Unknown 40 72 - Pred ? Tac ? MMF
6 M Chronic GN 55 128 - Pred ? CsA
7 M Chronic GN 48 189 - Pred ? CsA
8 M Chronic GN 52 56 ? Pred ? Tac ? MMF
9 M Unknown 41 104 ? Pred ? CsA
10 F Unknown 43 40 ? Pred ? CsA ? MMF
11 M Unknown 42 75 ? Pred ? CsA
12 M Unknown 49 258 ? Pred ? CsA
ESRD end stage renal disease, RCC renal cell carcinoma, GN glomerulonephritis, ACKD acquired cystic kidney disease, Pred
prednisolone, Tac tacrolimus, MMF mycophenolate mofetil, CsA cyclosporine
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received deceased kidney transplantation, and the
remaining three received kidneys from living donors.
The mean age at diagnosis of RCC was 48.4 years (SD
8 years; range 39.6–69.5 years), and the median time
from transplantation to diagnosis of malignancy was
6.1 years (range 1.2–21.5 years). The underlying causes
of end-stage renal failure were chronic glomerulone-
phritis in five patients and unknown in the remaining
seven. ACKD was found in 6 (50%) of the patients.
Only one patient presented with gross hematuria
while the remaining patients were totally asymptom-
atic. None of them had polycythemia. All RCC were
detected by ultrasound and later confirmed by
computed tomography. The ultrasound was arranged
when a post-transplant medical or surgical compli-
cation was suspected during follow-up.
For maintenance immunosuppressive therapy before
the diagnosis of RCC, five received triple immunosup-
pressive therapy (all were on corticosteroids, one on
cyclosporine, four on tacrolimus, one on azathioprine,
and four on mycophenolate mofetil) and seven patients
received two immunosuppressive agents (all were on
corticosteroids and cyclosporine). None of them had
induction therapy. Four patients received treatment for
acute cellular rejection before the diagnosis of RCC.
Five tumors were in the right kidney and six in the
left; while the remaining patient had bilateral tumors.
The histology included seven clear cell RCC (54%)
and six papillary RCC (46%). All the papillary RCC
were type 1. The mean (SD, range) tumor size was
3.2 (1.6, 1–6) cm. There were three, eight, and two
Furhman nuclear Grade 1, 2, and 3 tumors, respec-
tively. Eleven lesions were classified as pT1N0M0,
one as pT2N0M0, and one as pT2N1M0. Only one
tumor was metastasized at diagnosis. All patients
were treated successfully with radical nephrectomy.
Two had laparoscopic radical nephrectomy. The
patient who had bilateral RCC was treated with
bilateral nephrectomy.
Immunosuppressive therapy was modified in all
patients after the diagnosis of RCC with dosage
reduction in calcineurin inhibitors. For the four
patients receiving mycophenolate mofetil, the med-
ication was withdrawn in three and reduced in the
remaining patient. Azathioprine was withdrawn in the
single patient on azathioprine. On the other hand,
sirolimus was introduced for immunosuppression in
ten patients after nephrectomy.
After a median (range) follow-up of 38 (4–118)
months, two patients (16.7%) died. One died of
sepsis, and the other died of metastatic carcinoma
11 months after the diagnosis of RCC. The remaining
patients were alive with no evidence of recurrence of
malignancy at the time of the current report.
Table 2 Clinicopathologic characteristics of renal transplant recipients with RCC
Patient
number
Tumor
location
Tumor
size (cm)
Type Stage, Fuhrman Follow-up (month) Treatment
1 RK 2 Clear cell T1N0M0, G2 85 (Died) Lap nephrectomy
2 LK 5 Clear cell T1N0M0, G1 32 (Alive) Open nephrectomy
3 LK 2.3 Clear cell T1aN0M0, G2 25 (Alive) Open nephrectomy
4 RK 6 Papillary T1N0M0, G2 119 (Alive) Open nephrectomy
LK 1.5 Papillary T1N0M0, G2 Open nephrectomy
5 LK 4 Papillary T1N0M0, G1 68 (Alive) Open nephrectomy
6 RK 1.7 Clear cell T1N0M0, G2 45 (Alive) Open nephrectomy
7 LK 3 Clear cell T1N0M0, G2 21 (Alive) Open nephrectomy
8 RK 5.9 Papillary T1N0M0, G2 18 (Alive) Open nephrectomy
9 LK 4 Papillary T1N0M0, G1 73 (Alive) Open nephrectomy
10 LK 2.5 Papillary T2N1M0, G3 12 (Died) Open nephrectomy
11 RK 1 Clear cell T1N0M0, G2 50 (Alive) Open nephrectomy
12 RK 3.2 Clear cell T2N0M0, G3 4 (Alive) Lap nephrectomy
LK left kidney, RK right kidney, Lap laparoscopic
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Discussion
The prevalence of native kidney RCC after renal
transplantation in our locality is 1.3%—a figure similar
to that reported in literature which varies from 0.34 to
5%, depending on whether ultrasound screening was
performed [3, 7, 8]. ACKD has been described in native
kidneys of patients on long-term dialysis, with RCC
being diagnosed with increasing frequency in patients
with chronic renal failure. In most, but not all, instances
the cancers develop in association with ACKD. It has
been suggested that ACKD is an independent risk
factor for RCC [9, 10]. In patients with ACKD, the
prevalence is 19% and in patients with complex cysts, it
is 54% [8]. Papillary hyperplasia of cyst epithelium is
recorded in virtually every detailed pathology report of
tumors arising in ACKD and is the likely pathogenetic
basis for the development of renal tumors in cystic
kidneys complicating dialysis [11]. However, the
prevalence of ACKD and the behavior of cyst devel-
opment after renal transplantation are not well under-
stood. In the current series, half of our patients with
RCC were found to have ACKD. Since we have not
performed ultrasound examination for all our renal
transplant recipients, it is difficult to conclude that
ACKD is associated with a higher prevalence of native
kidney RCC. Nevertheless, patients without ACKD
may also develop RCC after kidney transplant. A recent
study showed that the occurrence of native renal cysts
that is even a single cyst confers a 1.7-fold higher risk of
developing RCC in renal transplant recipients [12].
Similar to other studies [13, 14], RCC was diagnosed at
a younger age in renal transplant recipients (mean age:
48.4 years in our series) than in the general population
(62.6 years) [15]. This is probably related to the higher
prevalence of ACKD and higher frequency of ultra-
sound examination in renal transplant population.
The prevalence of ACKD in renal transplant recip-
ients is lower than that in dialysis patients [8], possibly
related to the better renal function in renal transplant
recipients resulting in a slower cystic development. The
influence of immunosuppressive agents on cyst forma-
tion remains poorly understood. Unlike other locations,
immunosuppression appears not to increase the risk of
developing malignant changes in native kidneys, as
suggested by the identical incidence of RCC in heart
transplant patients and the general population. One may
argue that the development of post-renal transplant RCC
is more likely related to ESRD and dialysis therapy [16].
The diagnosis of native kidney RCC in renal
transplant recipients is difficult. It is typically an
incidental finding during ultrasound scan or computed
tomography for other clinical indications. In fact,
most tumors are small and asymptomatic at presen-
tation. In a retrospective study, the median native
kidney tumor size was 2 cm (pathologic T classifica-
tion: 12 pT1, 3 pT2, and 7 pT3) [17]. In another study
in which systematic ultrasound of native kidneys was
performed for 129 renal transplant recipients, 5
tumors, with a mean size of 2.5 cm, were diagnosed.
All of the tumors were pT1 lesions [3]. In our current
series, most patients (11 of 12) were asymptomatic
except one presenting with gross hematuria. Simi-
larly, pT1 disease was found in 10 patients with a
mean tumor size of 3.2 cm. The observation of a
higher prevalence of early-stage tumors in our trans-
plant recipients compared with the general population
is in accord with other studies [3, 17].
The percentage of clear cell RCC (54%) and
papillary RCC (46%) in our series is similar to that
reported in literature. The incidence of renal papillary
tumors is notably higher in hemodialysis and trans-
plant patients than in the general population in which
clear cell RCC accounts for 75–85% of tumors [18].
In contrast, papillary RCC represents 36 and 40% of
the histopathology in two Japanese series of renal
transplant recipients [17, 18]. The difference in
histological distribution between RCC in transplant
recipients and general population is probably related
to the presence of ACKD in dialysis and transplant
populations. Moreover, it may be related to the
genetic mechanism. While sporadic papillary RCC in
the general population usually shows allelic duplica-
tions of chromosomes 7 and 17 [19], this is not
common in RCC related to ESRD. Moreover, RCC
related to ESRD is typically not associated with p53
gene mutation [10].
Surgery is the preferred treatment as it is curative for
the majority of RCC without metastasis [20]. Radical
nephrectomy was performed for all of our patients and
the patient with bilateral RCC underwent bilateral
nephrectomy. Besides surgery, minimizing immuno-
suppression with the administration of mammalian
target of rapamycin inhibitors (m-TORi) represents
another approach to the management of de novo RCC.
m-TORi provide a strong cancer preventive effect
by blocking the growth and proliferation of tumor
cells, downregulating the PI3 K-Akt-mTOR pathway
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(frequently activated in cancer), and finally suppressing
angiogenesis [21]. Among tumors using the mTOR
pathway for activation, RCC is probably the most
sensitive tumor to m-TORi [22]. Both temsirolimus and
sirolimus are potent and specific inhibitors of mTOR. At
present, temsirolimus is approved by the European
Medicines Agency (EMEA) and the Food and Drug
Administration for treating advanced RCC. Of note,
temsirolimus is a sirolimus ester that is hydrolyzed to
sirolimus in patients, such that 74% of the circulating
drug following weekly temsirolimus is actually siroli-
mus. At trough, circulating sirolimus concentrations
exceed those of temsirolimus by approximately a factor
of ten [23]. Intravenous administration of temsirolimus
raises plasma concentrations of both temsirolimus and
sirolimus which contribute antitumor activity after the
administration of temsirolimus [24].
Screening for RCC is not recommended in the
general population due to its rarity. Despite the
incidence of RCC is increased in renal transplant
recipients and, in particular, recipients with ACKD [8],
the American Society of Transplantation has found no
evidence to support regular screening using ultrasound
or other radiology and urine cytology in renal trans-
plant recipients [25]. On the other hand, Schwarz et al.
[8] recommended a screening and management proto-
col in transplant recipients, incorporating the Bosniak
renal cyst classification. Recently Goh et al. also
advocated regular screening for renal cysts and RCC in
ESRD patients both on transplant waiting list and after
transplantation [12]. Inexpensive and noninvasive
renal ultrasound still provides the best predictive value
in screening and diagnosis of RCC in renal transplant
recipients [26] with a positive predictive value of 100%
[3, 27] and a negative predictive value of 92–94% [27,
28]. Goh et al. showed that routine ultrasound screening
is already effective in making early diagnosis with
excellent patient and graft outcomes in their center.
They proposed that screening should be performed
within a month of transplantation, then every 5 years of
those without cysts and every 2 years of those with
cysts so as to detect RCC early [12]. Although
computerized tomography (CT) scan findings of RCC
are similar for transplant recipients and general pop-
ulation, the presence of acquired multicystic renal
dysplasia affects the diagnostic performance of CT
scan. Terasawa et al. [29] and Sasagawa et al. [30]
reported a RCC detection rate of only 67 and 71%,
respectively, with CT scan.
With the improvement of life expectancy, cancer
now becomes a major cause of death following renal
transplantation. The cost-effectiveness of cancer
screening including RCC is still debatable. Currently,
the decision to screen remains the choice of the
managing physician without validated data and
evidence to support such practices. With increasing
data showing that a better prognosis of dialysis
patients and general population with RCC if the
malignancy is detected by screening rather than by
the appearance of symptoms [31, 32], it is now time
to revisit and reexamine the existing guidelines and to
consider cost-effective screening policies in all
kidney transplant candidates and recipients for native
renal cysts and RCC. More detailed and uniform
guidelines designed by the major international trans-
plantation societies are probably necessary.
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